Department of Medical Genetics, University Hospital of North-Norway, NO9038 Tromsø, Norway.
BMC Med Genet. 2014 Jan 21;15:12. doi: 10.1186/1471-2350-15-12.
The identification of disease causing, or putative disease causing, mutations in index patients with Charcot-Marie-Tooth disease (CMT) allows for genetic testing of family members. Relevant variants identified in index patients are of either definite, likely or uncertain pathogenicity. The main objective of this study was to make an evaluation of the family investigations performed as part of the assessment of genetic variants of unknown clinical significance (VUS).
Between 2004 and 2010 molecular genetic family investigations were requested for 87 family members from 41 families harbouring PMP22dup or genetic variants in GJB1, MPZ, MFN2 and NEFL. Relatives were tested for the family mutation and data from the requisitions were evaluated by means of statistical tools.
The results within each indication category are presented and discussed in detail. Twenty-two relatives (9 affected) from eight families were included in the segregation analyses, which invoked reclassification of three MFN2 mutations, two of which were de novo substitutions (c.2146_2148dup, c.692C > T). One MFN2 substitution was downgraded due to non-segregation (c.1709 A > G), and a MPZ substitution (c.103 G > A) upgraded due to segregation with the phenotype in the family.
The results allow for the evaluation of the patient phenotypes ascertained in families, as opposed to the phenotypic descriptions of index patients. They indicate that de novo MFN2 mutations are regularly found in patients with a classical CMT2 phenotype. They also demonstrate the importance of a precise clinical and neurophysiologic diagnosis of affected family members. This particularly applies for the examination of variants of uncertain clinical significance. Finally, the fact that 14,6% of affected relatives tested for (probable or certain) pathogenic mutations were mutation negative, demonstrates that clinical evaluation alone is not always sufficient in order to determine their diagnosis. We believe that the results will aid in the estimation and planning of resources required for the various aspects of family evaluations in CMT.
在遗传性运动感觉神经病(CMT)的索引患者中鉴定致病或疑似致病突变,可对其家族成员进行基因检测。在索引患者中发现的相关变异具有明确、可能或不确定的致病性。本研究的主要目的是评估作为遗传变异未知临床意义(VUS)评估一部分进行的家族调查。
在 2004 年至 2010 年间,对 41 个携带 PMP22dup 或 GJB1、MPZ、MFN2 和 NEFL 基因变异的家族中的 87 名家族成员进行了分子遗传学家族调查。对亲属进行了家族突变检测,并使用统计工具对需求数据进行了评估。
详细呈现和讨论了每个指征类别的结果。8 个家族的 22 名亲属(9 名受影响者)参与了分离分析,其中 3 个 MFN2 突变重新分类,其中 2 个为新生突变(c.2146_2148dup、c.692C > T)。一个 MFN2 替换因非分离而降级(c.1709 A > G),一个 MPZ 替换(c.103 G > A)因与家族表型分离而升级。
这些结果可用于评估家族中患者表型的确定,而不是索引患者的表型描述。结果表明,新生的 MFN2 突变经常出现在具有经典 CMT2 表型的患者中。结果还证明了对受影响家族成员进行精确临床和神经生理学诊断的重要性。这尤其适用于不确定临床意义的变异的检查。最后,在测试(可能或确定)致病性突变的受影响亲属中,有 14.6%的亲属为突变阴性,这表明仅临床评估并不总是足以确定其诊断。我们相信,这些结果将有助于评估遗传性运动感觉神经病(CMT)家族评估的各个方面所需资源的估算和规划。